ESTRO 2020 Abstract Book

S660 ESTRO 2020

ratio. This study aims to assess the clinical outcomes (local control and pain control, adverse events and overall survival) of patients with spine metastases who underwent SABR as part of their treatment scheme at a Between November 2010 and September 2018, we reviewed patients with spine metastasis treated with SABR in our department (Hospital Sírio- Libanês, Sao Paulo, Brazil). Spine SABR was performed in patients with oligometastases in different settings: radical (SABR only), postoperative (after decompression and/or fixation surgery) and reirradiation. We considered gastrointestinal, renal, sarcoma, melanoma and thyroid metastases as radioresistant tumors. Demographic, clinical and imaging data were obtained from the electronic medical records. Adverse events and local and pain control (failures) were defined as per available guidelines. Results 97 patients with spine metastases were included. The median age was 59 years (range 23 to 91). Most patients (82.3%, n=80) received SABR as the first local bone treatment while 12 patients (12%) underwent fixation and/or decompression surgery prior to SABR. Most common used SABR dose were 1x18Gy (24.5%) and 1x16Gy (20.2%). Fifty patients (51.6%) presented with radioresistant tumors. Two-year overall survival rate was 74.1% and median survival was 19 months. The local control rate at 2-year was 72.3%. In regards to pain control, 83.3% of patients had a complete response; 12.1%, partial response. Only 8.5% of patients developed failure pain during the clinical follow-up. Logistic regression for pain control at last follow-up did not demonstrate statistically significant differences among variables (ECOG-PS, tumor type, clinical settings and paraspinal mass, treatment dose). Vertebral compression fractures occurred in 10 patients (10.3%), of which, 5 cases in the reirradiation setting. Radiculopathy and myelopathy were not observed. Similarly, no grades III or IV toxicities This is the first study presenting a Brazilian experience with spine SABR and the results confirm its feasibility and safety. SABR was shown to produce good local and pain control rates with low adverse events rates. PO-1254 Palliative QUAD shots with chemotherapy in advanced Head and Neck Cancer: Is it the way to go? P. Tejaswi 1 , S. Sunkappa Dayashankara 2 , J. Kunigal Puttaswamy 2 , T. Boraiah 2 , N. Ramanand 2 , A. Katke 2 1 Mysore Medical College and Research Institute, Department of Radiation Oncology, Mysore, India ; 2 Kidwai Memorial Institute of Oncology, Department of Radiation Oncology, Bangalore, India Purpose or Objective To evaluate the feasibility and outcome of optimal response for palliation of symptoms, quality of life and toxicity using quad shots along with chemotherapy in advanced head and neck cancer patients who are not fit This study included 65 patients of Stage IV histologically proven squamous cell carcinoma of head and neck after multidisciplinary committee approval. Informed consent is taken from all patients for this study. On day 1, baseline symptoms and quality of life is documented followed by which concurrent radiosensitising agent Carboplatin (AUC2) administered only on day 1 and within 2-4 hours of chemotherapy administration, patients were treated with QUAD SHOT regimen of 14.4 Gy in 4 fractions with one fraction per day for 4 days without treatment interruptions in between from day 1 to day 4 via 3DCRT technique. After 3 weeks, patients who had palliation of symptoms and improvement in quality of life were considered for the Brazilian Institution. Material and Methods were seen. Conclusion for radical treatment. Material and Methods

next session of chemo-radiation and patients who had no benefit or severe reactions were not given further chemo- radiation and these patients were managed with best supportive care. Patients are followed up post 2 nd cycle of Quad shot at 3rd week, followed by monthly upto 3 months and every 3 months upto 1 year and assessed for palliation of symptoms and quality of life with validated questionnaire of EORTC QLQ-H&N 35 (English and kannada version), toxicity with RTOG toxicity grading and CTCAE Version 4.3. Results The present study revealed that QUAD SHOT regimen was able to produce palliation of symptoms and improvement in QoL in 80% of the patients and it was sustained upto 3 months with a median overall survival of 8 ± 0.411 months. However post phase 1, one patient reported Grade IV toxicity and two patients reported Grade IV toxicity after 2 nd phase RT and were managed with best supportive care